Goodsurance

Drug prices & Part D

With Open Enrollment Weeks Away, Medicare Rights Center Recaps What the Inflation Reduction Act Has Delivered for Part D in 2026

An August 27 analysis from the Medicare Rights Center outlines the drug law's current protections, including a first-ever Part D out-of-pocket cap and ten negotiated drug prices that took effect in January.

By the Goodsurance editorial teamAugust 30, 2026

With the 2027 Medicare Annual Enrollment Period less than seven weeks away, the Medicare Rights Center published an analysis on August 27 recapping the Inflation Reduction Act of 2022's changes to Part D prescription drug coverage and their current impact for beneficiaries.

Before the law's passage, Medicare Part D had no hard annual limit on what a beneficiary could owe out of pocket for covered drugs. Starting in 2025, the IRA established a cap, and the Medicare Rights Center notes that for 2026 that cap stands at 2,100 dollars, aligning Part D's protection with the limits long available in Medicare Advantage drug plans.

Ten Medicare-negotiated drug prices are now in effect for 2026. Here is what the 2022 drug law means for Part D enrollees heading into open enrollment.

Ten drugs selected in the law's first round of Medicare price negotiation entered the market at their negotiated prices on January 1, 2026. The medicines treat conditions including blood clots, diabetes, heart failure, autoimmune disorders, and certain cancers. CMS projected the negotiated prices would reduce what Part D enrollees pay out of pocket by 1.5 billion dollars annually and reduce Medicare's own drug spending by 6 billion dollars per year.

The analysis also notes that a third cycle of negotiations is now under way, covering fifteen additional drugs, with final prices expected later this fall.

The Medicare Rights Center highlighted open enrollment as the moment when beneficiaries should review their plan's drug formulary, verify their specific medications are covered at the lowest available cost-sharing tier, and confirm the plan passes through negotiated savings at the point of sale.

In plain words

The Medicare Rights Center explained what the 2022 drug law has done for people with Medicare Part D in 2026. There is now a limit on how much people pay for drugs in a year. In 2026, that limit is 2,100 dollars. Ten drugs that Medicare negotiated also cost less starting in January. A third round of negotiations is underway for fifteen more drugs. Open enrollment starts October 15. That is the time to check whether your drug plan still covers your medicines at the best price.

Source: Medicare Rights Center
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Comment Period Closes September 18 on How Drug Companies Must Apply Medicare-Negotiated Prices at Clinics and Doctor's Offices Starting in 2028

A CMS draft guidance describes the step-by-step process manufacturers must follow to make sure negotiated Medicare prices actually reach patients receiving infused or injected medicines at a doctor's office or outpatient clinic. Public comments are due September 18, 2026.

September 3, 2026

Drug prices & Part D

Medicare's Third Drug Negotiation Cycle Enters Its Final Month Before CMS Must Send Written Offers on 15 Drugs

CMS must issue final written maximum fair price offers to all 15 drug manufacturers in the third negotiation cycle by September 30. Companies then have until October 31 to accept or reject, with any agreed prices published by November 30 and taking effect in January 2028.

September 2, 2026

Drug prices & Part D

CMS Opens a New Database This Fall to Track Discounted Drugs Sold Through Medicare Part D

Starting October 1, 2026, safety-net health providers that buy drugs at a 340B discount can voluntarily report those Part D claims to CMS, filling a gap that has made it harder to enforce inflation rebate rules accurately.

August 29, 2026

Drug prices & Part D

Medicare Drug Plans Paid 587.7 Million Dollars for Prescriptions That Had Already Gone Over the Counter, OIG Finds

A federal audit found that from 2021 through 2023, Part D plans paid hundreds of millions of dollars for five drugs that had already switched from prescription-only to over-the-counter status, because CMS did not update its reference files quickly enough.

August 28, 2026

Drug prices & Part D

Federal Appeals Court Rejects Drug Manufacturer's Challenge to Medicare Price Negotiation Program

The U.S. Court of Appeals for the D.C. Circuit dismissed a pharmaceutical company's lawsuit arguing that the Medicare drug price negotiation program is unconstitutional, continuing a series of judicial losses for industry opponents of the program.

August 28, 2026

Drug prices & Part D

Noncovered Drug Versions Are Inflating What Medicare Pays for Certain Infused Medicines, Federal Watchdog Reports

OIG examined five quarters of Part B drug billing data and found that four of six drug billing codes had payment rates pushed up because CMS included the price of noncovered self-administered versions in its calculations.

August 26, 2026